Drug dependence: Neuropharmacology and management

Journal of Pharmacy and Pharmacology

Volumn 54, Issue 7, 2002, Pages 885-895

  Deslandes, P N ^a   Pache, D M ^a   Sewell, R D E ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; ACAMPROSATE; ACETYLCHOLINE; AMFEBUTAMONE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; BACLOFEN; BICUCULLINE; BUPRENORPHINE; CENTRAL STIMULANT AGENT; CLONIDINE; CLOZAPINE; COCAINE; DESIGNER DRUG; FLUPENTIXOL; HALOPERIDOL; LOFEXIDINE; METHADONE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; OPIATE DERIVATIVE; PIMOZIDE; RITANSERIN; SEROTONIN; SEROTONIN 2 ANTAGONIST; SERTINDOLE; SULPIRIDE; UNINDEXED DRUG;

ADDICTION; ANTIBODY SPECIFICITY; BRAIN REGION; DOPAMINERGIC TRANSMISSION; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG EFFECT; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; HIPPOCAMPUS; HUMAN; IMMUNE SYSTEM; MAINTENANCE THERAPY; MESOLIMBIC DOPAMINERGIC SYSTEM; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NEUROTRANSMITTER UPTAKE; NONHUMAN; NUCLEUS ACCUMBENS; PATIENT ATTITUDE; PREFRONTAL CORTEX; PSYCHOTHERAPY; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; VENTRAL TEGMENTUM; WITHDRAWAL SYNDROME; ADAPTATION; BIOLOGICAL MODEL; BRAIN; DOSE RESPONSE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADAPTATION, PHYSIOLOGICAL; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN; MODELS, BIOLOGICAL; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS; HUMANS;

EID: 0035990528     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/002235702760088992     Document Type: Review

References (114)

1. Neuroanatomical sites mediating the motivational effects of opioids mapped by the conditioned place preference paradigm in rats
2. Synthetic analgesics: Stereochemical considerations
3. Recent developments in treating opiate misuse
4. Effects of the κ-opioid receptor agonist U-50,488 on morphine-induced place preference conditioning in the developing rat
5. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes
6. Intracranial self-administration of morphine into the ventral tegmental area in rats
7. Acute effects of cocaine on human brain activity and emotion
8. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa receptor type
9. 3 dopamine receptors
10. Pharmacology of nociceptin and its receptor: A novel therapeutic target
11. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: Evidence that dopamine is taken up in vivo by noradrenergic terminals
12. Cocaine vaccines: Antibody protection against relapse in a rat model
13. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: Sustained effects of treatment
14. Cocaine and amphetamine depress striatal GABAergic synaptic transmission through D2 dopamine receptors
15. Structure and function of the dopamine transporter
16. Where is the locus in opioid withdrawal?
17. Discriminative stimulus properties of narcotic analgesic drugs
18. S-coupled, GM1 ganglioside-regulated opioid receptor functions
19. Variations in methadone treatment practices: Results from a national study
20. Effect of haloperidol on (+)-amphetamine self-administration
21. The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion
22. Blockade of cocaine reinforcement in rats with the dopamine blocker pimozide, but not with the noradrenergic blockers phentolamine and phenoxybenzamine
23. International Union of Pharmacology. XII. Classification of opioid receptors
24. A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use
25. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats
26. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats
27. PCR differential display identifies a rat brain mRNA that is transcriptionally regulated by cocaine and amphetamine
28. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membrane
29. Heroin and cocaine self-administration in rats: Mediation by separate neuronal systems
30. Fentanyl-induced conditional place preference: Lack of associated neurochemical events
31. Outpatient treatment of "crack" cocaine smoking with flupenthixol decanoate
32. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: A preliminary trial
33. Opioid blockade attenuates acquisition and expression of cocaine-induced place preference conditioning in rats
34. Cortical dopaminergic involvement in cocaine reinforcement
35. Enhancing cocaine metabolism with butyryl-cholinesterase as a treatment strategy
36. Reinforcing and discriminative stimulus effects of calcium-acetyl homotaurinate in animals
37. Activation of memory circuits during cue-elicited cocaine craving
38. Pharmacologic interventions for the treatment of opioid dependence and withdrawal
39. Immunization of rats reduces nicotine distribution to brain
40. Evidence for the coexistence of dopamine and CCK in mesolimbic neurones
41. Chronic morphine increases hippocampal acetylcholine release: Possible relevance in drug dependence
42. Active cocaine immunization attenuates the discriminative properties of cocaine
43. Opioids excite dopamine neurons by hyperpolarisation of local interneurons
44. Behavioural and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat
45. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model
46. Intra-ventral tegmental area injection of rat cocaine and amphetamine-regulated transcript peptide 55-102 induces locomotor activity and promotes conditioned place preference
47. 2 dopamine receptors in rat brain
48. Drugs of abuse: Anatomy, pharmacology and function of reward pathways
49. Neuroscience of addiction
50. Decreased drug craving during inpatient detoxification with ibogaine
51. The anti-craving drug acamprosate inhibits the conditioned place aversion induced by naloxone-precipitated morphine withdrawal in rats
52. Genes in drug abuse
53. Antibody-catalyzed degradation of cocaine
54. Blockade of D-1 receptors by SCH23390 antagonises morphine-induced place preference conditioning
55. 3H]-hydroxy-N,N di-n-propyl-2-aminotetralin
56. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers
57. Neuroleptics block the positive reinforcing effects of amphetamine but not of morphine as measured by place conditioning
58. Anatomy of CNS opioid receptors
59. Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications
60. Drug replacement treatments: Is amphetamine substitution a horse of a different colour?
61. 2 antagonist ritanserin in drug abuse
62. Olanzapine attenuates the reinforcing effects of cocaine
63. 2 pKi values
64. Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor
65. Motivational properties of κ and μ opioid receptor agonists studied with taste and place preference conditioning procedure
66. Reinforcing properties of morphine and naloxone revealed by conditioned place preferences: A procedural examination
67. Drug reinforcement studied by the use of place conditioning in rat
68. Orphanin FQ/nociceptin blocks acquisition of morphine place preference
69. Molecular basis of long term plasticity underlying addiction
70. Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain
71. Reinforcing effects of morphine in the nucleus accumbens
72. The development of a conditioned place preference to morphine: Effects of microinjections into various CNS sites
73. μ-Opposing actions of the κ-opioid receptor
74. Cellular mechanism for anti-analgesic action of agonists of the κ-opioid receptor
75. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts
76. Intracerebral self-administration of amphetamine by rhesus monkeys
77. Orphanin FQ effects on morphine-induced dopamine release in the accumbens of rats
78. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D receptor agonist
79. A new concept on the mode of interaction of narcotic analgesics with receptors
80. Contrasting actions of acute or chronic paroxetine and fluvoxamine on morphine withdrawal-induced place conditioning
81. Orphanin FQ: A neuropeptide that activates an opioid like G protein-coupled receptor
82. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: Most antidepressants selectively block norepinephrine uptake
83. Baclofen suppression of cocaine self-administration: Demonstration using a discrete trials procedure
84. Atypical neuroleptics increase self-administration of cocaine: An evaluation of a behavioural screen for antipsychotic activity
85. Dose-dependent conditioned place preference produced by etonitazene and morphine
86. Molecular mechanism of drug reinforcement and addiction
87. Ibogaine and cocaine abuse: Pharmacological interactions at dopamine and serotonin receptors
88. A preliminary investigation of ibogaine: Case reports and recommendations for further study
89. Motivational effects of opioids: Influence of D-1 versus D-2 receptor antagonists
90. Influence of chronic lithium treatment upon the motivational effects of opioids: Alteration in the effects of mu- but not kappa-opioid receptor ligands
91. Motivational properties of opioids: Evidence that an activation of receptors mediates reinforcement processes
92. Examination of the neurochemical substrates mediating the motivational effects of opioids: Role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors
93. Chronic morphine induces visible changes in the morphology of mesolimbic dopamine neurons
94. Cocaine reward models: Conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice
95. 3 dopamine receptors in the brain reward circuits of human cocaine fatalities
96. Drugs of abuse: Behavioural principles, methods and terms
97. Do antidepressants affect motivation in conditioned place preference?
98. Sertindole antagonizes morphine-, cocaine-, and methamphetamine-induced place preference in rat
99. Increase of extracellular dopamine in the prefrontal cortex: A trait of drugs with antidepressant potential?
100. Mianserin markedly and selectively increases extracellular dopamine in the prefrontal cortex as compared to the nucleus accumbens of the rat
101. Dopaminergic mediation of the discriminative stimulus effects of bupropion in rats
102. Naloxone blockade of amphetamine place preference conditioning
103. Drug reward and brain circuitry: Recent advances and future directions
104. An opiate-receptor gene family reunion
105. Time course of the development of behavioral sensitization and dopamine receptor up-regulation during binge cocaine administration
106. Intravenous self-administration of drugs in rats
107. Cloning of a gene for the human dopamine D4 receptor with high affinity for the antipsychotic clozapine
108. cDNA cloning of an orphan opiate receptor gene family member and its splice variant
109. Acamprosate: A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification
110. Drugs and substance misuse: Opioids
111. 4 receptor ligands: Relation to antipsychotic action
112. Continuous cocaine administration produces persisting changes in brain neurochemistry and behavior
113. Disruption of cocaine and heroin self-administration following kinetic acid lesions of the nucleus accumbens